WO2001080879A3 - Colorectal cancer vaccines and diagnosis - Google Patents

Colorectal cancer vaccines and diagnosis Download PDF

Info

Publication number
WO2001080879A3
WO2001080879A3 PCT/EP2001/004456 EP0104456W WO0180879A3 WO 2001080879 A3 WO2001080879 A3 WO 2001080879A3 EP 0104456 W EP0104456 W EP 0104456W WO 0180879 A3 WO0180879 A3 WO 0180879A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
colorectal cancer
cancer vaccines
casb81
polynucleotides
Prior art date
Application number
PCT/EP2001/004456
Other languages
French (fr)
Other versions
WO2001080879A2 (en
Inventor
Y De Bassols Carlota Vinals
Swann Ronain Jean-Thoma Gaulis
Thierry Coche
Torben Orntoft
Original Assignee
Smithkline Beecham Biolog
Y De Bassols Carlota Vinals
Gaulis Swann Ronain Jean Thoma
Thierry Coche
Torben Orntoft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Y De Bassols Carlota Vinals, Gaulis Swann Ronain Jean Thoma, Thierry Coche, Torben Orntoft filed Critical Smithkline Beecham Biolog
Priority to AU2001265886A priority Critical patent/AU2001265886A1/en
Publication of WO2001080879A2 publication Critical patent/WO2001080879A2/en
Publication of WO2001080879A3 publication Critical patent/WO2001080879A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the use of CASB81 polypeptides and polynucleotides and immunogenic compositions thereof in the treatment or diagnosis of colorectal cancer.
PCT/EP2001/004456 2000-04-20 2001-04-19 Colorectal cancer vaccines and diagnosis WO2001080879A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001265886A AU2001265886A1 (en) 2000-04-20 2001-04-19 Compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0009907.7 2000-04-20
GBGB0009907.7A GB0009907D0 (en) 2000-04-20 2000-04-20 Novel compounds

Publications (2)

Publication Number Publication Date
WO2001080879A2 WO2001080879A2 (en) 2001-11-01
WO2001080879A3 true WO2001080879A3 (en) 2002-05-16

Family

ID=9890383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004456 WO2001080879A2 (en) 2000-04-20 2001-04-19 Colorectal cancer vaccines and diagnosis

Country Status (3)

Country Link
AU (1) AU2001265886A1 (en)
GB (1) GB0009907D0 (en)
WO (1) WO2001080879A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075350A2 (en) * 2005-01-13 2006-07-20 Fondazione Centro Dan Raffaele Del Monte Tabor Use of the pof1 gene product for cosmetic and/or therapeutic use of skin associated disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2001016318A2 (en) * 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2001016318A2 (en) * 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FURUSE MIKIO ET AL: "Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin.", JOURNAL OF CELL BIOLOGY, vol. 141, no. 7, 29 June 1998 (1998-06-29), pages 1539 - 1549, XP002129738, ISSN: 0021-9525 *

Also Published As

Publication number Publication date
AU2001265886A1 (en) 2001-11-07
WO2001080879A2 (en) 2001-11-01
GB0009907D0 (en) 2000-06-07

Similar Documents

Publication Publication Date Title
IL245955B (en) Immunogenic compositions for the prevention and treatment of meningococcal disease
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL157993A0 (en) Molecular conjugates for use in cancer treatment and methods for the preparation thereof
AU6147401A (en) Compositions and methods for the treatment of cancer
HUP0102039A3 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
PL366626A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
EP1545599A4 (en) Immunogenic compositions and diagnostic and therapeutic uses thereof
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1349485A4 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001080879A3 (en) Colorectal cancer vaccines and diagnosis
WO2003039484A3 (en) Novel compositions and methods for cancer
EP1259255A4 (en) Pai-2 conjugates for the treatment and imaging of cancer
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005049072A3 (en) Therapeutic cancer vaccine with fragments of trag-3
AU2001280443A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001274973A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP